Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on December 27, 2021. The filing reports on a material amendment to a Securities Purchase Agreement (SPA) originally entered into on September 24, 2021, regarding a $15 million financing round with institutional investors.
Key Financial Metrics and Obligations
The filing details a financing structure involving senior secured convertible promissory notes and warrants:
- Total Financing: $15 million aggregate purchase price.
- First Closing (Sept 24, 2021): $5 million purchase price for $5.3 million principal in Notes; 361,158 Warrants issued.
- Second Closing (Nov 5, 2021): $10 million purchase price for $10.6 million principal in Notes; 722,317 Warrants issued.
- Total Notes Principal: $15.9 million ($5.3 million + $10.6 million).
- Total Warrants Issued: 1,083,475 shares.
- Standard Conversion Price: $5.87 per share.
The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes and Amendments
On December 27, 2021, the Company and investors executed a Letter Agreement amending the SPA. The primary material change is a temporary reduction in the conversion price for the Notes:
- Temporary Conversion Price: Reduced to $4.50 per share.
- Effective Period: 14 trading days commencing December 28, 2021, and ending January 14, 2022.
- Reversion: Following the 14-day window, the conversion price reverts to the initial $5.87 per share.
- Warrants: No change to the exercise price of the Warrants.
Outlook, Risks, and Contingencies
The Letter Agreement includes certain conditions that the Company must satisfy in connection with the transaction. The Company has registered the resale of shares issuable upon conversion of the Notes and exercise of Warrants pursuant to a Registration Rights Agreement. The Notes and Warrants were issued unregistered under Section 4(a)(2) of the Securities Act.
Key Facts for Investor Verification
- Verify the specific conditions the Company must satisfy under the December 27, 2021 Letter Agreement.
- Confirm the total outstanding principal of the Notes ($15.9 million) and the impact of the temporary $4.50 conversion price on potential dilution.
- Review the Security Agreement and Patent Security Agreement (Exhibits 10.4 and 10.5) to understand the collateral securing the Notes.
- Monitor the trading volume and price of the Common Stock (ENSC) during the 14-day conversion window to assess conversion activity.